deliv rel in-lin consid effect fx
worth stock buy-back quarter oper basi revenu
increas y/i adjust ep increas y/i re-affirmed guidanc given
result though note reflect fx rate april
decreas share count share repurchas
manag state continu expect growth come
price come increas volum exist product balanc
come newer product includ apoquel
us segment particular show weak quarter vs
estim consensu estim larg driven miss
companion anim segment vs estim consensu
dermatolog portfolio grow sale apoquel
cytopoint growth off-set declin older product rimadyl
face competit elanco/petx gallipr manag also point
gener take share clavamox antibiot revolut treatment
heartworm state see price pressur
consolid custom us expect trend consolid spread
eu clinic form buy group
manag believ compani increas invest dtc advertis
begin show year progress particular campaign focu
increas awar dermatolog condit atop dermat well
creat campaign simparica believ increas market
penetr also grow pie continu view best posit
anim health compani valuat keep us sidelin
adjust ep feel stock fairli valu may room come
apoquel cytopoint simparica becom establish market
forc find asset pipelin bd sustain top-lin growth
quarterli annual ep usd
consensu number thomson reuter receiv gmt
barclay capit inc and/or one affili seek busi
compani cover research report result investor awar
firm may conflict interest could affect object report investor
consid report singl factor make invest decis
return equiti ttm
link barclay live interact chart
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
appear fairli valu view
fundament appear intact oper effici
gain larg complet put pressur
sustain top-lin growth apoquel simparica
cytopoint repres attract asset
obviou much extend recent
string pearl
upsid case assum strong recoveri
global anim health market next two year
per year zoeti achiev gm
expans longer term factor
drive upsid case ep
downsid case assum stagnat
anim health market lower uptak
derm product growth pace
soft industri outlook gm improv
longer term factor lead
downsid ep
dougla tsao herebi certifi view express research report accur reflect person view
subject secur issuer refer research report part compens directli indirectli relat
specif recommend view express research report
barclay research produc invest bank barclay bank plc affili collect individu barclay
avail disclosur
compani subject research report current import disclosur regard compani pleas refer
http //publicresearch barclay com altern send written request barclay research complianc seventh avenu floor
new york ny call
analyst respons prepar research report receiv compens base upon variou factor includ firm total
revenu portion gener invest bank activ profit revenu market busi
potenti interest firm invest client research respect asset class cover analyst
author contribut research report research analyst unless otherwis indic
public date top report reflect local time report produc may differ releas date provid
gmt
analyst regularli conduct site visit view materi oper cover compani barclay polici prohibit accept
payment reimburs cover compani travel expens visit
http //publicresearch barcap com/s/rd htm order access barclay research conflict manag polici statement pleas refer
procedur pleas
barclay research depart produc variou type research includ limit fundament analysi equity-link analysi
quantit analysi trade idea recommend contain one type barclay research may differ contain
type barclay research whether result differ time horizon methodolog otherwis barclay research depart
oper independ absa research depart absa research produc absa bank limit act corpor
invest bank divis part barclay africa group limit affili invest bank barclay bank plc elig
client may receiv research report research depart may reach differ conclus may contain differ
conflict forecast recommend trade idea
price sourc thomson reuter last avail close price relev trade market unless anoth time sourc
